# Golimumab for the Treatment of Refractory Behcet's Uveitis

> **NCT04218565** · PHASE2 · TERMINATED · sponsor: **Wenjie Zheng** · enrollment: 1 (actual)

## Conditions studied

- Behcet Syndrome
- Uveitis

## Interventions

- **BIOLOGICAL:** Golimumab (GOL)

## Key facts

- **NCT ID:** NCT04218565
- **Lead sponsor:** Wenjie Zheng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-15
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** only one patient enrolled
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04218565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04218565, "Golimumab for the Treatment of Refractory Behcet's Uveitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04218565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*